期刊文献+

慢性阻塞性肺疾病患者对短效支气管扩张剂的急性舒张反应 被引量:6

Acute bronchodilation response in patients with chronic obstructive pulmonary disease after short-term bronchodilator inhalation
原文传递
导出
摘要 目的探讨中度至极重度慢性阻塞性肺疾病(COPD)患者对短效支气管扩张剂沙丁胺醇的急性舒张反应。方法收集2009年1月至2011年12月安徽医科大学第一附属医院呼吸内科中、重度COPD稳定期患者156例,其中男性123例,女性33例,年龄50~76岁,平均年龄(58±6)岁。停用支气管扩张剂48h后,先测定基线肺通气功能,吸入沙丁胺醇400μg30min后再测定肺通气功能,比较吸入沙丁胺醇前及吸入30min后1S用力呼气容积(FEV3)的改善情况。结果与基线肺通气功能比较,全部156例中重度COPD患者FEV.平均增加150ml。FEV。%pred平均增加9.1%,其中36例(23.1%)吸入支气管舒张剂后FEV,较吸入前改善≥12%,同时增加200ml。支气管舒张试验阳性组吸入前FEV。%pred为36.3±7.9,阴性组吸入前FEV1%pred为42.6±10.2。支气管舒张试验阳性组FEV,改善程度明显好于阴性组,阳性组舒张前、后FEV.%pred之间差异有显著性(P〈0.05)。阴性组吸入支气管舒张剂前的平均基线FEV,%pred高于阳性组,两者差异有显著性(P〈0.05)。结论部分COPD患者对短效支气管扩张剂显示较好的舒张反应,支气管舒张试验可呈阳性。 Objective To investigate the degree of acute improvement in spirometric indices after short-term bronchodilator inhalation among chronic obstructive pulmonary disease (COPD) patients. Methods 156 stable patients with moderate-to-very-severe COPD were enrolled between January 2009 to December 2011 (123 males and 33 females), with the age ranged from 50 to 76 (58 ± 6) years. After wash-out of bronchodilator, spirometry was performed before and 30 min following 400 μg salbutamol inhalation. Forced expiratory volume in one second ( FEVI ) were compared between before and 30min following 400μg salbutamol inhalation. Results Compared with baseline, mean improvements were 150 ml in FEVI and absolute increase was 9.1% in FEVI% pred. In these patients, 36 cases(23.1% ) had /〉12% and I〉200 ml improvements in FEVl. Mean pre- bronchodilator FEV % pred were 36.3 ± 7.9 in positive bronchodilator response patients and 42.6 ±10.2 in negative bronchodilator response patients. The data showed the improvement of positive patients was better than negative patients. FEV % of positive patients had significant difference in before and after (P 〈 0. 05 ). The mean baseline of negative patients was higher than positive patients before inhaled. (P 〈 0. 05 ) Conclusion Partial patients with moderate-to-very-severe COPD demonstrate meaningful increase in lung, function followin administration of inhaled short-term bronchodilators.
出处 《中华肺部疾病杂志(电子版)》 CAS 2013年第4期9-11,共3页 Chinese Journal of Lung Diseases(Electronic Edition)
关键词 肺疾病 慢性阻塞性 支气管扩张剂 可逆性 呼吸功能试验 Chronic obstructive pulmonary disease Bronchodilator Reversibility Respiratoryfunction tests
  • 相关文献

参考文献16

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 2Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [ J ]. Eur Respir J, 2004, 23 ( 1 ) : 932- 946.
  • 3文富强.重视慢性阻塞性肺疾病的合并症[J].中华肺部疾病杂志(电子版),2013,6(2):1-3. 被引量:19
  • 4李羲,黄华萍.重视慢性阻塞性肺疾病诊治中的几个问题[J].中华肺部疾病杂志(电子版),2010,3(1):1-3. 被引量:4
  • 5Pellegrino R, Viegi G, Bmsasco V, et al. Interpretative strategies for lung function tests[ J]. Eur Respir J, 2005, 26(5 ) : 948-968.
  • 6Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term brouchodilator responses[J]. Chest, 2003, 123(5): 1441-1449.
  • 7Borg BM, Reid DW, Wahers EH, et al. Bronchodilator reversibility testing: laboratory practices in Australia and NewZealand[ J]. Med J Aust, 2004, 180(12) : 610-613.
  • 8Hansen JE, Casaburi R, Goldberg AS. A statistical approach for assessment of bronchodilator responsiveness in pulmonary function testing[Jl. Chest, 1993, 104(4): 1119-1126.
  • 9Routine ebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group[J]. Chest, 1997, 112(6): 1514-1521.
  • 10Criteria for the assessment of reversibility in airways obstruction. Report of the Committee on Emphysema, American College of Chest Physicians[J]. Chest, 1974, 65(5):552-553.

二级参考文献29

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 3GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
  • 4Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
  • 5Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
  • 6冉丕鑫 王辰 姚婉贞 等.我国部分地区慢性阻塞性肺疾病流行病学研究[J].中华结核和呼吸杂志,2007,.
  • 7Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? [J]. Lancet, 2007, 370(9589): 797-799.
  • 8Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study [J]. RepirRes, 2010, 11:63.
  • 9Crisafulli E, Costi S, Luppi F, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation [J]. Thorax, 2008, 63(6): 487-492.
  • 10Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem ananlysisof major causes of early death in patients hospitalized with COPD exacerbation[ J ]. Chest, 2009, 136 (2) : 376-380.

共引文献8255

同被引文献76

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部